WallStreetZenWallStreetZen

NASDAQ: MCRB
Seres Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for MCRB

Based on 3 analysts offering 12 month price targets for Seres Therapeutics Inc.
Min Forecast
$4.00+226.53%
Avg Forecast
$6.67+444.24%
Max Forecast
$10.00+716.33%

Should I buy or sell MCRB stock?

Based on 3 analysts offering ratings for Seres Therapeutics Inc.
Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MCRB stock forecasts and price targets.

MCRB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-06-07
lockedlocked$00.00+00.00%2024-05-09
lockedlocked$00.00+00.00%2024-05-08

1 of 1

Forecast return on equity

Is MCRB forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is MCRB forecast to generate an efficient return on assets?
Company
-43.49%
Industry
30.97%
MCRB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MCRB earnings per share forecast

What is MCRB's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
-$1.03
Avg 2 year Forecast
-$0.69
Avg 3 year Forecast
-$0.19

MCRB revenue forecast

What is MCRB's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$300.0k-99.76%
Avg 2 year Forecast
$104.0M-18.04%
Avg 3 year Forecast
$9.6M-92.46%
MCRB's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MCRB revenue growth forecast

How is MCRB forecast to perform vs Biotechnology companies and vs the US market?
Company
5.81%
Industry
64.4%
Market
11.24%
MCRB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MCRB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MCRB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MCRB$1.23$6.67+444.24%Strong Buy
OTLK$7.96$42.28+431.16%Strong Buy
CHRS$1.64$9.00+448.78%Strong Buy
GUTS$3.94$18.00+356.85%Strong Buy
LCTX$1.00$6.50+550.00%Strong Buy

Seres Therapeutics Stock Forecast FAQ

Is Seres Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: MCRB) stock is to Strong Buy MCRB stock.

Out of 3 analysts, 2 (66.67%) are recommending MCRB as a Strong Buy, 1 (33.33%) are recommending MCRB as a Buy, 0 (0%) are recommending MCRB as a Hold, 0 (0%) are recommending MCRB as a Sell, and 0 (0%) are recommending MCRB as a Strong Sell.

If you're new to stock investing, here's how to buy Seres Therapeutics stock.

What is MCRB's earnings growth forecast for 2024-2026?

(NASDAQ: MCRB) Seres Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.64%.

Seres Therapeutics's earnings in 2024 is -$82,683,000.On average, 5 Wall Street analysts forecast MCRB's earnings for 2024 to be -$155,991,196, with the lowest MCRB earnings forecast at -$193,853,137, and the highest MCRB earnings forecast at -$128,730,599. On average, 4 Wall Street analysts forecast MCRB's earnings for 2025 to be -$104,120,337, with the lowest MCRB earnings forecast at -$149,933,285, and the highest MCRB earnings forecast at -$56,035,672.

In 2026, MCRB is forecast to generate -$28,775,075 in earnings, with the lowest earnings forecast at -$28,775,075 and the highest earnings forecast at -$28,775,075.

What is MCRB's revenue growth forecast for 2024-2027?

(NASDAQ: MCRB) Seres Therapeutics's forecast annual revenue growth rate of 5.81% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.4%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.24%.

Seres Therapeutics's revenue in 2024 is $126,847,000.On average, 1 Wall Street analysts forecast MCRB's revenue for 2024 to be $45,434,329, with the lowest MCRB revenue forecast at $45,434,329, and the highest MCRB revenue forecast at $45,434,329. On average, 1 Wall Street analysts forecast MCRB's revenue for 2026 to be $15,744,509,441, with the lowest MCRB revenue forecast at $15,744,509,441, and the highest MCRB revenue forecast at $15,744,509,441.

In 2027, MCRB is forecast to generate $1,449,355,092 in revenue, with the lowest revenue forecast at $1,449,355,092 and the highest revenue forecast at $1,449,355,092.

What is MCRB's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: MCRB) forecast ROA is -43.49%, which is lower than the forecast US Biotechnology industry average of 30.97%.

What is MCRB's Price Target?

According to 3 Wall Street analysts that have issued a 1 year MCRB price target, the average MCRB price target is $6.67, with the highest MCRB stock price forecast at $10.00 and the lowest MCRB stock price forecast at $4.00.

On average, Wall Street analysts predict that Seres Therapeutics's share price could reach $6.67 by Jun 7, 2025. The average Seres Therapeutics stock price prediction forecasts a potential upside of 444.24% from the current MCRB share price of $1.23.

What is MCRB's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: MCRB) Seres Therapeutics's current Earnings Per Share (EPS) is -$0.60. On average, analysts forecast that MCRB's EPS will be -$1.03 for 2024, with the lowest EPS forecast at -$1.28, and the highest EPS forecast at -$0.85. On average, analysts forecast that MCRB's EPS will be -$0.69 for 2025, with the lowest EPS forecast at -$0.99, and the highest EPS forecast at -$0.37. In 2026, MCRB's EPS is forecast to hit -$0.19 (min: -$0.19, max: -$0.19).

What is MCRB's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: MCRB) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.